Quarterly report [Sections 13 or 15(d)]

SIGNIFICANT ACCOUNTING POLICIES (Tables)

v3.26.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Information about significant segment expenses regularly provided to the CODM is as follows (in thousands):

Information about significant segment expenses regularly provided to the CODM is as follows (in thousands):

 

                         
    March 31,  
    (in thousands)  
    2026     2025     Change  
Research and development expenses:                        
Direct expenses – TNX - 102 SL   $ 1,472     $ 1,034     $ 438  
Direct expenses – TNX - 801     1,059       319       740  
Direct expenses – TNX - 1500     4,277       382       3,895  
Direct expenses – TNX - 1900     891       136       755  
Direct expenses – TNX - 4200     320       131       189  
Direct expenses – TNX - 4800     1,394       —       1,394  
Direct expenses – Other programs     768       322       446  
Internal staffing, overhead and other     8,032       5,112       2,920  
Total research & development   $ 18,213     $ 7,436     $ 10,777  
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows:

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows:

 

    March 31,
2026		     March 31,
2025		  
    (in thousands)  
Cash and cash equivalents   $ 185,470     $ 131,716  
Restricted cash     538       903  
Total   $ 186,008     $ 132,619  
Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of March 31, 2026, and 2025, are as follows:

Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of March 31, 2026, and 2025, are as follows:

 

    2026     2025  
Warrants to purchase common stock     26,239       29,021  
Options to purchase common stock     2,131,964       674,134  
Totals     2,158,203       703,155